Almirall presents long-term interim results from Phase 3b ADlong study

Almirall (LBTSF) presents long-term interim results from the ongoing Phase 3b ADlong study evaluating the efficacy and safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis. Lebrikizumab delivered near-complete skin clearance and itch relief for up to four years for patients with moderate-to-severe atopic dermatitis, while maintaining its established safety profile. Interim findings from the first year of the ADlong Phase 3b study were presented at the American Academy of Dermatology Annual Meeting, taking place March 27-31 in Denver. In the ADlong study, the majority of patients achieved near-complete skin clearance and clinically meaningful itch relief with up to four years of continuous lebrikizumab treatment. Most patients were on lebrikizumab monotherapy, and the majority of patients achieved these results without topical corticosteroids. In addition, 80% achieved these outcomes with lebrikizumab monthly maintenance dosing during the study. The safety of lebrikizumab in this first year of the ADlong study was consistent with the established safety profile in patients with moderate-to-severe atopic dermatitis, and no new safety signals were observed. The majority of adverse events were mild or moderate and did not lead to discontinuation. Reported treatment-related adverse events in the study included nasopharyngitis, URTI and conjunctivitis. The ADlong study is ongoing and will continue for an additional year of treatment. These results reinforce the sustained response achieved with lebrikizumab over time in patients with moderate-to-severe atopic dermatitis, building on recently published findings showing that continued treatment for two years enabled a substantial proportion of responder population to achieve complete skin clearance and itch relief4.